
Dec 6 (Reuters) - Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial.
The trial, which enrolled 22 patients, studied safety and preliminary efficacy of the company's therapy, odronextamab, in combination with chemotherapy in patients with Diffuse Large B-Cell Lymphoma or DLBCL.
Odronextamab belongs to a class of treatments called bispecific antibodies that are designed to attach to a cancer cell and an immune cell, bringing them together so that the body's immune system can kill the cancer.
At the 160 mg dose of the combination, patients showed 100% complete response rate, the company said.
DLBCL is a fast-growing blood cancer that affects the lymphatic system, which is a network of tissues, vessels and organs that help fight infection in the body. It involves changes in the B cells, a particular type of white blood cell.
B-cell counts were cleared completely after the first dose of the therapy, the company said in a presentation at the American Society of Hematology Annual Meeting.
Most patients completed six cycles of the combination at both 80 mg and 160 mg dose levels. The higher dose has been selected for further studies.
Data also suggested that when combining odronextamab with the chemotherapy regimen known as CHOP, deep and lasting responses were achieved without the need for rituximab.
"Part of our focus here at Regeneron is to develop bispecifics which are extremely potent and which don't require a very heavy burdensome additional cocktail of drugs to be combined with because their activity in itself is very potent," said Aafia Chaudhry, global program head.
The company will be initiating enrollment of patients for the second part of the study to see how effective the combination is in comparison with the combination of rituximab and chemotherapy, the current standard of care treatment approved for DLBCL.
"Our strategy is to replace rituximab rather than to add on to rituximab," Chaudhry added.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
latest_posts
- 1
Pick Your Number one Sort Of Music - 2
Kids with smartphones by age 12 are at higher risk of health issues, study finds - 3
‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism - 4
The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland? - 5
Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
Tehran synagogue damaged by missile strike according to Iranian media
Language Learning Stages: Which One Gets Your Vote?
Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
'Senseless violence' erupts at Christmas tree lighting; 4 injured
Senegal president signs tough new anti-LGBT law doubling jail terms
FACT FOCUS: Trump sows confusion on number of childhood vaccinations
The 15 Most Powerful Forerunners in Business
The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.













